Altimmune (ALT) Change in Acquisitions & Divestments (2017 - 2026)

Altimmune (ALT) has 7 years of Change in Acquisitions & Divestments data on file, last reported at $39.6 million in Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $39.6 million, up 4.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $154.6 million (up 38.77% YoY), and the FY2025 annual result was $153.0 million, up 75.15% from the prior year.
• Change in Acquisitions & Divestments rose to $39.6 million in Q1 2026 per ALT's latest filing, from $9.4 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $105.5 million in Q2 2025 and troughed at $9.4 million in Q4 2025.
• A 4-year average of $31.9 million and a median of $26.4 million in 2023 frame the typical range for Change in Acquisitions & Divestments.
• On a YoY basis, Change in Acquisitions & Divestments climbed as much as 441.28% in 2025 and fell as far as 65.0% in 2025.
• A 4-year view of Change in Acquisitions & Divestments shows it stood at $25.9 million in 2023, then gained by 3.78% to $26.8 million in 2024, then plunged by 65.0% to $9.4 million in 2025, then surged by 321.65% to $39.6 million in 2026.
• Business Quant data shows ALT's Change in Acquisitions & Divestments at $39.6 million in Q1 2026, $9.4 million in Q4 2025, and $105.5 million in Q2 2025.